Supernus Pharmaceuticals says FDA grants seven years of orphan-drug exclusivity for Onapgo
SUPN•Supernus Pharmaceuticals said the FDA granted Onapgo seven years of orphan-drug exclusivity.
1. FDA exclusivity
Supernus Pharmaceuticals said the FDA granted seven years of orphan-drug exclusivity for Onapgo.
